Consiglio Nazionale delle Ricerche

Tipo di prodottoArticolo in rivista
TitoloInfluence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.
Anno di pubblicazione2015
FormatoElettronico
Autore/iDefferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.
Affiliazioni autoriDepartment of Pathology, Istituto Giannina Gaslini, Genova 16148, Italy. Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Vienna 1090, Austria. Northern Genetics Service, Newcastle upon Tyne NEI 3 BZ, UK. Department of Pathology, Oslo University Hospital Rikshopitalet, Oslo 0424, Norway. Département de Biologie et de Pathologie Médicales, Gustave Roussy Cancer Campus, Villejuif 94800, France. Department of Pathology, Medical School of Valencia, University of Valencia, Valencia 46010, Spain. Laboratoire de Recherche Translationnelle, Centre Léon-Bérard, Lyon 69008, France. Unité de Génétique Somatique et Cytogénétique, Institut Curie, Paris Cedex 05 75248, France. Epidemiology, Biostatistics and Committees Unit, Istituto Giannina Gaslini, Genova 16148, Italy. Department of Haematology-Oncology, Istituto Giannina Gaslini, Genova 16148, Italy. Pediatric Oncology Research Unit, Lausanne University Hospital (CHUV), Lausanne 1011, Switzerland. Department of Paediatric Oncology, Southampton General Hospital, Southampton S016 6YD, UK. Cancer Cytogenetique and Molecular Cytogenetique Laboratory, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. Northern Institute for Cancer Research, Newcastle University, Newcastle NE2 4HH, UK. Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisbon 1649-016, Portugal. Department of Clinical Genetics, Göteborg University, Sahlgrenska University Hospital, Göteborg 413 45, Sweden. Institute of Electronics, Computer and Telecommunication Engineering, National Research Council, Genova 16149, Italy. INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Paris Cedex 05 75248, France; Département d'Oncologie Pédiatrique, Institut Curie, Paris Cedex 05 75248, France. Center for Medical Genetics, Ghent University Hospital, Ghent 9000, Belgium. Department of Paediatric Haematology and Oncology, Charles University and University Hospital Motol, Prague 15008, Czech Republic. Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia 46009, Spain. Laboratory of Neuroblastoma, Onco/Haematology Laboratory, University of Padua, Pediatric Research Institute (IRP)-Città della Speranza, Corso Stati Uniti 4, Padova 35127, Italy.
Autori CNR e affiliazioni
  • STEFANO PARODI
Lingua/e
  • inglese
AbstractBackground:The prognostic impact of segmental chromosome alterations (SCAs) in children older than 1 year, diagnosed with localised unresectable neuroblastoma (NB) without MYCN amplification enrolled in the European Unresectable Neuroblastoma (EUNB) protocol is still to be clarified, while, for other group of patients, the presence of SCAs is associated with poor prognosis.Methods:To understand the role of SCAs we performed multilocus/pangenomic analysis of 98 tumour samples from patients enrolled in the EUNB protocol.Results:Age at diagnosis was categorised into two groups using 18 months as the age cutoff. Significant difference in the presence of SCAs was seen in tumours of patients between 12 and 18 months and over 18 months of age at diagnosis, respectively (P=0.04). A significant correlation (P=0.03) was observed between number of SCAs per tumour and age. Event-free (EFS) and overall survival (OS) were calculated in both age groups, according to both the presence and number of SCAs. In older patients, a poorer survival was associated with the presence of SCAs (EFS=46% vs 75%, P=0.023; OS=66.8% vs 100%, P=0.003). Moreover, OS of older patients inversely correlated with number of SCAs (P=0.002). Finally, SCAs provided additional prognostic information beyond histoprognosis, as their presence was associated with poorer OS in patients over 18 months with unfavourable International Neuroblastoma Pathology Classification (INPC) histopathology (P=0.018).Conclusions:The presence of SCAs is a negative prognostic marker that impairs outcome of patients over the age of 18 months with localised unresectable NB without MYCN amplification, especially when more than one SCA is present. Moreover, in older patients with unfavourable INPC tumour histoprognosis, the presence of SCAs significantly affects OS.
Lingua abstractinglese
Altro abstract-
Lingua altro abstract-
Pagine da290
Pagine a295
Pagine totali-
RivistaBritish Journal of Cancer
Attiva dal 1947
Editore: H K Lewis and Co, Ltd. - London
Paese di pubblicazione: Regno Unito
Lingua: inglese
ISSN: 0007-0920
Titolo chiave: British Journal of Cancer
Titolo proprio: British Journal of Cancer.
Titolo abbreviato: Br. J. Cancer
Titolo alternativo: BJC
Numero volume della rivista112
Fascicolo della rivista2
DOI10.1038/bjc.2014.557
Verificato da refereeSì: Internazionale
Stato della pubblicazionePublished version
Indicizzazione (in banche dati controllate)-
Parole chiaveMYCN, DDX1, Gain, FISH
Link (URL, URI)-
Titolo parallelo-
Data di accettazione-
Note/Altre informazioni-
Strutture CNR
  • IEIIT — Istituto di elettronica e di ingegneria dell'informazione e delle telecomunicazioni
Moduli CNR-
Progetti Europei-
Allegati
Full text (documento privato )
Tipo documento: application/pdf